ClinicaliQ Trial Snapshot
- Study to Investigate Efficacy, Safety, and Tolerability of Zibotentan/Dapagliflozin Compared to Dapagliflozin in Participants With Chronic Kidney Disease and High Proteinuria (ZENITH High Proteinuria) — Active Not Recruiting • Phase III • NCT06087835.
- ZENITH High Proteinuria Trial Summary.
- Adding zibotentan to dapagliflozin versus dapagliflozin alone for reducing protein loss in chronic kidney disease patients.
Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
This is a Phase III, randomised, multicentre, double-blinded study to evaluate efficacy, safety and tolerability of treatment with zibotentan/dapagliflozin and dapagliflozin alone in participants with chronic kidney disease (CKD) and high proteinuria Conditions: Chronic Kidney Disease With High Proteinuria Interventions: Zibotentan/Dapagliflozin, Dapagliflozin Lead Sponsor: AstraZeneca Planned Enrollment: 1835 participants